Novanta Inc. supplies precision technology components and subsystems to medical and advanced industrial equipment manufacturers worldwide. While its common shares trade on Nasdaq under NOVT, the NOVTU ticker identifies a separate security: the company's 6.50% Tangible Equity Units due 2028. This hybrid instrument combines debt and equity characteristics, which is why some investors track it for its regular cash distributions paired with exposure to the underlying shares. I also checked this using Tickeron’s AI Screener to see how the unit compares with similar hybrid securities in the sector.
Novanta dates back to 1968 and operated as GSI Group, Inc. until it adopted its current name in May 2016. Headquartered in Bedford, Massachusetts, the company operates through two main segments: Automation Enabling Technologies and Medical Solutions. It provides laser beam steering and scanning systems, laser sources, photonics, precision motion control, robotic end-of-arm tooling, vision and RFID technologies, as well as medical devices including insufflators and pumps. Customers are primarily OEMs serving medical, life sciences, and advanced industrial markets.
The business focuses on designing and manufacturing specialized components that OEMs incorporate into their equipment. This approach positions Novanta as a supplier across areas such as surgical robotics, ophthalmology, advanced manufacturing, and automation, rather than a maker of finished consumer products.
NOVTU itself is not common stock. It is a tangible equity unit issued by Novanta in November 2025. Each $50.00 unit includes a prepaid stock purchase contract that requires delivery of common shares on a mandatory settlement date and a senior amortizing note with an initial principal of $8.74. The note pays quarterly installments of $0.8125 from February 2026 through November 1, 2028, resulting in an aggregate annual cash payment equal to 6.50% of the stated amount.
On the settlement date of November 1, 2028, each purchase contract converts automatically into Novanta common shares. The number of shares ranges from a minimum of 0.3729 (when the stock price meets or exceeds the threshold appreciation price of $134.0842) to a maximum of 0.4662 (when the stock price is at or below the reference price of $107.26). The amortizing notes represent direct, unsecured, and unsubordinated obligations of the company.
From what I see, NOVTU draws interest for its hybrid profile that balances income and equity participation. Investors receive a steady 6.50% annual cash distribution via the amortizing note while the purchase contract offers upside exposure to Novanta shares up to the threshold appreciation price. This combination can suit those looking for current income alongside limited equity upside.
Novanta's longer-term growth ties to demand in precision medicine, medical and surgical robotics, and automation in life sciences and manufacturing. The company generates revenue across the United States, Germany, and additional markets with a diversified OEM customer base. Because its components are embedded in regulated medical devices and precision systems, the firm can benefit from recurring demand and higher switching costs, though it remains sensitive to capital spending and healthcare trends.
Before considering NOVTU, investors should note several risks. The amortizing note is an unsecured, unsubordinated obligation, so holders bear credit risk linked to Novanta's financial condition. The equity component can decline in value if the share price falls, since conversion occurs into a fixed range of shares whose worth depends on the price at settlement. Below the reference price, holders receive the maximum shares, but overall value can still drop.
The units carry no voting or dividend rights on the underlying shares until settlement, and their market price can shift with interest rates, the company's stock performance, and credit conditions. At the company level, Novanta faces cyclical industrial and medical capital spending, competition from larger manufacturers, technological changes, and acquisition integration risks. As a hybrid, NOVTU may also experience lower liquidity than the common stock and price behavior that diverges from the shares.
Novanta specializes in precision photonics, vision, and motion-control technology for medical and advanced industrial OEMs, and NOVTU offers one distinctive route to exposure. As a tangible equity unit, it combines a 6.50% annual cash distribution with limited equity participation, setting it apart from standard share ownership. For those who understand its structure and conversion mechanics, the security illustrates how companies can employ innovative instruments to raise capital while providing income-focused investors with a customized risk profile.
In my own analysis process, I frequently turn to Tickeron’s AI Screener to scan for securities that fit specific criteria like yield, volatility, and industry exposure. The platform uses technical indicators, fundamentals, and AI signals to surface ideas efficiently. It has helped me compare instruments such as NOVTU against peers without sifting through endless data manually.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day moving average for NOVTU crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 2 of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 28 of 36 cases where NOVTU Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 9 of 12 cases where NOVTU's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for NOVTU turned negative on October 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 8 similar instances when the indicator turned negative. In 6 of the 8 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (1.448). P/E Ratio (0.000) is within average values for comparable stocks, (5.350). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.470). NOVTU has a moderately high Dividend Yield (0.057) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (32.028).
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. NOVTU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NOVTU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ElectronicEquipmentInstruments